Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Ortho Panel Says 'No' To Medtronic DIAM Spine Device

This article was originally published in The Gray Sheet

Executive Summary

Minimally invasive interspinous spacer did not get the support of an FDA advisory panel in the face of serious questions about Medtronic's study design.

You may also be interested in...



Boston Scientific Buys Vertiflex For $465M To Add Minimally Invasive Lumbar Procedure

Vertiflex sells the Superion indirect decompression system, a minimally invasive device to treat lumbar spinal stenosis. Boston Scientific expects it to bring in $60m in revenue in 2019 to its Neuromodulation business.

In Case You Missed It: Top 10 Gray Sheet Stories In February

Our coverage of the highly anticipated release of the revised ISO 13485 international medical device quality systems standard attracted the most attention from Gray Sheet readers last month. Also popular: stories about FDA photography during facility inspections, European postmarket surveillance reforms, and policy updates focused on human factors.

Ortho Panel Green Lights VertiFlex’s Superion Spine Spacer

A majority of FDA advisors say the device intended to treat lumbar spinal stenosis has a positive risk-benefit profile but should require an extended postmarket trial to evaluate its safety and efficacy over a longer time period.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT034994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel